Skip to Main Content

Author Details

J. Carl Barrett
Oncology R&D
1966
579
110
PMIDPaper TitleJournal TitlePublished Year
36043882Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.Clin Cancer Res2023
37379430Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.Clin Cancer Res2023
37434977Impact of DNA damage repair alterations on prostate cancer progression and metastasis.Front Oncol2023
37263992Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.Nat Commun2023
36849516Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.Nat Commun2023
36849494Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.Nat Commun2023
34866317Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.Mol Oncol2022
35921524Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.Clin Cancer Res2022
34979999Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.BMC Cancer2022
35177674Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.Sci Rep2022
34230008Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.Cancer Discov2021
33741979Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.Nat Commun2021
33818572Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis.J Vis Exp2021
34500047Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.Ann Oncol2021
34606929Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.Ann Oncol2021
34663950Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.Br J Cancer2021
34742578Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.Gynecol Oncol2021
34830984Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.Cancers (Basel)2021
34250423Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health.JCO Precis Oncol2021
34359745Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition.Cancers (Basel)2021
32217756Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.J Immunother Cancer2020
32017048Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases.Clin Pharmacol Ther2020
31953314Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response.Clin Cancer Res2020
32091082Development, Validation, and Regulatory Considerations for a Liquid Biopsy Test.Clin Chem2020
32943458<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.Clin Cancer Res2020
32870995Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC's Analytical Variables Working Group.Clin Chem2020
32923890Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in <i>MET</i>-Amplified Gastric Cancer.JCO Precis Oncol2020
31477768Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA.Sci Rep2019
31492872Proliferation Tumour Marker Network (PTM-NET) for the identification of tumour region in Ki67 stained breast cancer whole slide images.Sci Rep2019
28841389Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.J Clin Oncol2018
30082476Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.Clin Cancer Res2018
30353044Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.Br J Cancer2018
30377213A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.EMBO Mol Med2018
30385821pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.Br J Cancer2018
29635390RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.Ann Oncol2018
29215764An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.Hum Mutat2018
29066505A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers.Clin Cancer Res2018
29348681Impact of a five-dimensional framework on R&amp;D productivity at AstraZeneca.Nat Rev Drug Discov2018
28073847Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors.Clin Cancer Res2017
28489509AKT Inhibition in Solid Tumors With AKT1 Mutations.J Clin Oncol2017
28223274Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.Clin Cancer Res2017
28187516Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.Clin Pharmacol Ther2017
28370296Validation of a Multiplexed Gene Signature Assay for Diagnosis of Canine Cancers from Formalin-Fixed Paraffin-Embedded Tissues.J Vet Intern Med2017
28392986Prioritisation of structural variant calls in cancer genomes.PeerJ2017
29245897Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum.Oncotarget2017
28751247Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial.J Thorac Oncol2017
28525389Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.Oncotarget2017
27733477Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.Clin Cancer Res2017
27112209Defining actionable mutations for oncology therapeutic development.Nat Rev Cancer2016
28649177Nucleic acid extraction from formalin-fixed paraffin-embedded cancer cell line samples: a trade off between quantity and quality?BMC Clin Pathol2016
  • 1 - 50 of 579

Recommended Authors

Stephen Chung
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1993
Number of shared co-authors 0
James DeGregori
University of Colorado Anschutz Medical Campus
Career Start Year 1991
Number of shared co-authors 1
Robert Brown
Division of Cancer and Ovarian Cancer Action Research Centre, Imperial College London
Career Start Year 1990
Number of shared co-authors 11
Teresa L Johnson-Pais
University of Texas Health San Antonio
Career Start Year 1990
Number of shared co-authors 2
John W Phillips
University of California los angeles
Career Start Year 1988
Number of shared co-authors 1
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 10
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 12
Frederick E Domann
University of Iowa
Career Start Year 1986
Number of shared co-authors 5
Alfredo A Molinolo
University of California
Career Start Year 1984
Number of shared co-authors 7
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 25
Parmjit S Jat
UCL Institute of Prion Diseases
Career Start Year 1981
Number of shared co-authors 2
Molly Kulesz-Martin
Oregon Health & Science University
Career Start Year 1980
Number of shared co-authors 2
David M Thomas
Garvan Institute of Medical Research
Career Start Year 1980
Number of shared co-authors 9
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 12
Fabien Calvo
Universite de Paris-Cite
Career Start Year 1979
Number of shared co-authors 11
Alexander Kamb
Inc. 30301 Agoura Rd.
Career Start Year 1979
Number of shared co-authors 2
Robert H Shoemaker
National Cancer Institute
Career Start Year 1978
Number of shared co-authors 7
Colin S Cooper
Norwich Medical School, University of East Anglia
Career Start Year 1978
Number of shared co-authors 11
Webster K Cavenee
Ludwig Institute for Cancer Research, University of California San Diego
Career Start Year 1977
Number of shared co-authors 6
Christopher C Benz
Buck Institute for Research on Aging
Career Start Year 1977
Number of shared co-authors 13
Scott M Lippman
Moores Cancer Center, university of california san diego
Career Start Year 1977
Number of shared co-authors 14
James Koropatnick
Western University, Lawson Health Research Institute
Career Start Year 1975
Number of shared co-authors 1
Hartmut Land
University of Rochester Medical Center, Wilmot Cancer Institute
Career Start Year 1974
Number of shared co-authors 0
Joe W Gray
Oregon Health and Science University
Career Start Year 1974
Number of shared co-authors 23
William E Grizzle
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 7
Raju Kucherlapati
Harvard Medical School
Career Start Year 1973
Number of shared co-authors 17
Arnold J Levine
Simons Center for Systems Biology, Institute for Advanced Study
Career Start Year 1967
Number of shared co-authors 4
John D Minna
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1967
Number of shared co-authors 21
Stephen B Baylin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Career Start Year 1963
Number of shared co-authors 11
Norman E Sharpless
National Cancer Institute
Career Start Year 1945
Number of shared co-authors 8

Collaborators

Cynthia A Afshari
Amgen Inc.
Co-authored papers 26
Andrew Berchuck
Duke School of Medicine
Co-authored papers 22
Vladimir Larionov
National Cancer Institute
Co-authored papers 20
Natalay Kouprina
National Cancer Institute
Co-authored papers 19
Greg Solomon
National Institute of Environmental Health Sciences
Co-authored papers 18
Zhongwu Lai
Oncology R&D
Co-authored papers 16
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 12
George L Maxwell
Women's Health Integrated Research Center, Inova Health System
Co-authored papers 12
Michael J Birrer
Co-authored papers 7
Justin Johnson
Co-authored papers 6
Jonathan R Dry
Present Address: Tempus Labs Inc.
Co-authored papers 6
Jung-Hyun Kim
Korea Polar Research Institute
Co-authored papers 5
William B Isaacs
The Brady Urological Institute, The Johns Hopkins School of Medicine
Co-authored papers 5
John N Weinstein
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 5
Adam Pavlicek
Monoceros Biosystems LLC
Co-authored papers 4
Kelli Bramlett
Co-authored papers 4
Pasi A J??nne
Dana-Farber Cancer Institute
Co-authored papers 4
Elizabeth Murphy
Co-authored papers 4
William Marston Linehan
Co-authored papers 4
Maxim Koriabine
Co-authored papers 4
David W Kane
Co-authored papers 3
Pierre R Bushel
Co-authored papers 3
Gideon M Blumenthal
Oncology Center of Excellence
Co-authored papers 3
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 3
William J Howat
Cancer Research UK Cambridge Institute
Co-authored papers 3
Thomas Ried
Center for Cancer Research, National Cancer Institute
Co-authored papers 3
Jean Claude Zenklusen
National Cancer Institute
Co-authored papers 3
John Otstot
Co-authored papers 3
José Baselga
Co-authored papers 3
Release 1.2